Vascular disrupting agents: A novel mechanism of action in the battle against non-small cell lung cancer

Oncologist

Volumn 14, Issue 6, 2009, Pages 612-620

  Gridelli, Cesare ^a   Rossi, Antonio ^a   Maione, Paolo ^a   Rossi, Emanuela ^a   Castaldo, Vincenzo ^a   Sacco, Paola Claudia ^a   Colantuoni, Giuseppe ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

ASA404; CA4P; Ligand directed VDAs; NPI 2358; NSCLC; Vascular disrupting agents

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANG 453; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4 PHOSPHATE; DENIBULIN; DOCETAXEL; DOXORUBICIN; EPC 2407; FLAVONOID; FLUOROURACIL; FOSBRETABULIN; MITOFLAXONE; MX 116407; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; N ACETYLCOLCHINOL PHOSPHATE; NPI 2358; OXI 2021; PACLITAXEL; PLACEBO; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; TUBULIN; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANGIOGENESIS; ANOREXIA; ASTHENIA; BLOOD PRESSURE; BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER PAIN; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SPECIFICITY; ENDOTHELIUM CELL; FATIGUE; FEVER; HUMAN; ILEUS; ISCHEMIA; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PERICYTE; PRIORITY JOURNAL; QT INTERVAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR NECROSIS; TUMOR VASCULARIZATION; VISUAL DISORDER; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; ENDOTHELIAL CELLS; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; PERICYTES; PIPERAZINES; STILBENES; SULFONAMIDES; XANTHONES;

EID: 68049108414     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0287     Document Type: Review

References (48)

1. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65-71.
2. Siemann DW, Bibby MC, Dark GG et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005;11:416-420.
3. Cooney MM, Heeckeren W, Bhakta S et al. Drug insight: Vascular disrupting agents and angiogenesis-novel approaches for drug delivery. Nat Clin Pract Oncol 2006;3:682- 692.
4. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002.CACancer J Clin 2005;55:74 -108.
5. Kakolyris S, Fox S, Koukourakis M et al. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39. Br J Cancer 2000;82:844-851.
6. Konerding MA, Fait E, Gaumann A. 3D microvascular architecture of precancerous lesions and invasive carcinomas of the colon. Br J Cancer 2001; 84:1354 -1362.
7. Tozer GM, Lewis S, Michalowski A et al. The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma. Br J Cancer 1990;61:250 -257.
8. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 1982;45:136 -139.
9. Hinnen P, Eskens F. Vascular disrupting agents in clinical development. Br J Cancer 2007;96:1159 -1165.
10. O'Hanlon LH. Taking down tumors: Vascular disrupting agents entering clinical trials. J Natl Cancer Inst 2005;97:1244 -1245.
11. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004;100:2491-2499.
12. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415- 427.
13. Burrows FJ, Thorpe PE. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Accad Sci U S A 1993;90:8996 -9000.
14. Gaya AM, Rustin GJ. Vascular disrupting agents: A new class of drug in cancer therapy. Clin Oncol (R Coll Radiol) 2005;17:277-290.
15. Mahindroo N, Liou JP, Chang JY et al. Antitubulin agents for the treatment of cancer-a medicinal chemistry update. Expert Opin Ther Pat 2006;16: 647-691.
16. Wilson WR, Li AE, Cowan DS et al. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 1998;42:905-908.
17. Murata R, Overgaard J, Horsman MR. Comparative effects of combretastatin A-4 disodium phosphate and 5, 6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 2001;77:195-204.
18. Philpott M, Baguley BC, Ching LM. Induction of tumour necrosis factoralpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1995;36:143-148.
19. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003;4:141-148.
20. Philpott M, Ching LM, Baguley BC. The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a costimulator with other inducers of tumour necrosis factor. Eur J Cancer 2001;37:1930 -1937.
21. Pruijn FB, van Daalen M, Holford NH et al. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1997;39:541-546.
22. Siim BG, Lee AE, Shalal-Zwain S et al. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2003;51:43-52.
23. McKeage MJ, Fong P, Jeffery M et al. 5,6-dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: A phase I safety study of a vascular disrupting agent. Clin Cancer Res 2006;12:1776 -1784.
24. McKeage M. Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24(suppl 18):389s.
25. McKeage MJ, von Pawel J, Reck M et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008;99:2006 -2012.
26. McKeage MJ, Reck M, Jameson MB et al. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800 mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 2009; April 29 [Epub ahead of print].
27. McKeage MJ, Jameson MB. Comparison of safety and efficacy between squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II study of DMXAA (ASA404). J Clin Oncol 2008;26(suppl 15): 441s.
28. National Cancer Institute. PDQ National Cancer Institute Clinical Trials Database. Available at http://www.cancer.gov/clinical-trials, accessed February 23, 2009.
29. Pettit GR, Singh SB, Hamel E et al. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989;45: 209-211.
30. Pettit GR, Temple C Jr, Narayanan VL et al. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 1995;10: 299-309.
31. Vincent L, Kermani P, Young LM et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 2005;115:2992-3006.
32. Dark GG, Hill SA, Prise V et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997; 57:1829 -1834.
33. Horsman MR, Ehrnrooth E, Ladekarl M et al. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys 1998;42: 895-898.
34. Malcontenti-Wilson C, Muralidharan V, Skinner S et al. Combretastatin A-4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Clin Cancer Res 2001;7:1052-1060.
35. Tozer GM, Prise VE, Wilson J et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: Intravital microscopy and measurement of vascular permeability. Cancer Res 2001; 61:6413- 6422.
36. Tozer GM, Prise VE, Wilson J et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res 1999;59:1626 -1634.
37. Ng QS, Goh V, Carnell D et al. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007;67:1375-1380.
38. Mandeville HC, Goh V, Ng QS et al. Volumetric perfusion CT assessment of concurrent combretastatin-A4-phosphate (CA4P) and radiotherapy (RT) in non-small cell lung cancer. J Clin Oncol 2008;26(suppl 15):634s.
39. Grosios K, Loadman PM, Swaine DJ et al. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 2000;20:229 -233.
40. Nelkin BD, Ball DW. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep 2001;8:157-160.
41. Horsman MR, Murata R, Breidahl T et al. Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Adv Exp Med Biol 2000;476:311-323.
42. Ozawa Y, Sugi NH, Nagasu T et al. E7070, a novel sulfonamide agent with potent antitumor activity in vitro and in vivo. Eur J Cancer 2001;37:2275-2282.
43. Hande KR, Hagey A, Berlin J et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: Results of a phase 1 study. Clin Cancer Res 2006;9:2834 -2840.
44. Mauer AM, Cohen EE, Ma PC et al. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thor Oncol 2008;3:631-636.
45. Dragnev KH, Rigas JR, DisalvoWM et al. A phase I trial of ABT-751 and carboplatin (C) in patients (pts) with previously treated non-small cell lung cancer (NSCLC). J Clin Oncol 2006;24(suppl 18):674s.
46. Kanoh K, Kohno S, Asari T et al. Phenylahistin: A new mammalian cell cycle inhibitor produced by Aspergillus ustus. Bioorg Med Chem Lett 1997;7:2847-2852.
47. Mita AC, Yee LK, Papadopoulos KP et al. Phase I study of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas. J Clin Oncol 2008;26(suppl 15):159s.
48. Anderson H, Price P, Blomley M et al. Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques. Br J Cancer 2001;85:1085-1093.